{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:49Z","timestamp":1790351509650,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The distribution of tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML) is influenced by the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). While most TKI-transporter interactions are well established, limited information is available for the novel STAMP inhibitor asciminib, and divergent data exist for the role of P-gp in nilotinib and bosutinib efflux. This study used in vitro cellular and vesicular transport assays to evaluate the substrate and inhibitory profiles of all TKIs currently used in CML treatment. It was confirmed that asciminib is a substrate of both P-gp and BCRP, similar to imatinib and dasatinib, whereas bosutinib was modestly transported by P-gp only. For P-gp, asciminib appeared to be a weak inhibitor, comparable to dasatinib, whereas nilotinib remained the most potent inhibitor. Conversely, asciminib demonstrated notable potency against BCRP, ranking it among the strong inhibitors imatinib, nilotinib, and ponatinib, while dasatinib and bosutinib were less effective. These findings provide further insight into the efflux transporter interactions of asciminib and updated evidence on nilotinib and bosutinib transport by P-gp, with implications for drug resistance and treatment optimization in CML.<\/jats:p>","DOI":"10.1007\/s00280-026-04891-z","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:49:11Z","timestamp":1778590151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-5468","authenticated-orcid":false,"given":"N. E.","family":"Verhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.W.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.M.W.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. H.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. M.A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.W.M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Koenderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. G.M.","family":"Russel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"24","key":"4891_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 34(24):2851\u20132857","journal-title":"J Clin Oncol"},{"issue":"1","key":"4891_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-025-01242-8","volume":"15","author":"L Busque","year":"2025","unstructured":"Busque L, Beaudet M, Harnois M, Moussa H, Szuber N, Mollica L et al (2025) Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study. Blood Cancer J 15(1):35","journal-title":"Blood Cancer J"},{"issue":"4","key":"4891_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","volume":"477","author":"V Kumar","year":"2022","unstructured":"Kumar V, Singh P, Gupta SK, Ali V, Verma M (2022) Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem 477(4):1261\u20131279","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"4891_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1872312813666190207150207","volume":"13","author":"J Blanc Mettral","year":"2019","unstructured":"Blanc Mettral J, Faller N, Cruchon S, Sottas L, Buclin T, Schild L et al (2019) Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. Drug Metab Lett 13(2):102\u2013110","journal-title":"Drug Metab Lett"},{"issue":"2","key":"4891_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, Cambareri AC et al (2006) OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2):697\u2013704","journal-title":"Blood"},{"key":"4891_CR6","doi-asserted-by":"crossref","unstructured":"Verhagen NE, Koenderink JB, Blijlevens NMA, Janssen J, Russel FGM (2023) Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia. Pharmaceutics15(11): 2535","DOI":"10.3390\/pharmaceutics15112535"},{"issue":"1","key":"4891_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1046\/j.1365-2141.1996.273807.x","volume":"92","author":"AG Turkina","year":"1996","unstructured":"Turkina AG, Baryshnikov AY, Sedyakhina NP, Folomeshkina SV, Sokolova MA, Choroshco ND, Stavrovskaya AA (1996) Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen. Br J Haematol 92(1):88\u201396","journal-title":"Br J Haematol"},{"key":"4891_CR8","doi-asserted-by":"crossref","unstructured":"Dalle Fratte C, Polesel J, Gagno S, Posocco B, De Mattia E, Roncato R et al (2023) Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis. Int J Mol Sci24(4):3303","DOI":"10.3390\/ijms24043303"},{"issue":"4","key":"4891_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s44318-025-00361-z","volume":"44","author":"D Kurre","year":"2025","unstructured":"Kurre D, Dang PX, Le LTM, Gadkari VV, Alam A (2025) Structural insights into binding-site access and ligand recognition by human ABCB1. EMBO J 44(4):991\u20131006","journal-title":"EMBO J"},{"issue":"4","key":"4891_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Ap\u00e1ti A, Mag\u00f3csi M, N\u00e9met K, Orfi L et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158(4):1153\u20131164","journal-title":"Br J Pharmacol"},{"issue":"11","key":"4891_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2009.166","volume":"23","author":"A Davies","year":"2009","unstructured":"Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ et al (2009) Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23(11):1999\u20132006","journal-title":"Leukemia"},{"issue":"8","key":"4891_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.031302","volume":"38","author":"M Dohse","year":"2010","unstructured":"Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF et al (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38(8):1371\u20131380","journal-title":"Drug Metab Dispos"},{"issue":"23","key":"4891_CR13","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68(23):9809\u20139816","journal-title":"Cancer Res"},{"issue":"4","key":"4891_CR14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1021\/mp2001022","volume":"8","author":"S Shukla","year":"2011","unstructured":"Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP et al (2011) Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm 8(4):1292\u20131302","journal-title":"Mol Pharm"},{"issue":"22","key":"4891_CR15","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1182\/blood.V114.22.3763.3763","volume":"114","author":"P Perini","year":"2009","unstructured":"Perini P, Redaelli S, Piazza R, Viltadi M, Boschelli F, Gambacorti C (2009) Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein. Blood 114(22):3763","journal-title":"Blood"},{"key":"4891_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-015-0179-4","volume":"8","author":"S Redaelli","year":"2015","unstructured":"Redaelli S, Perini P, Ceccon M, Piazza R, Rigolio R, Mauri M et al (2015) In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol 8:81","journal-title":"J Hematol Oncol"},{"key":"4891_CR17","first-page":"63","volume":"6","author":"K Skoglund","year":"2013","unstructured":"Skoglund K, Moreno SB, Baytar M, J\u00f6nsson JI, Gr\u00e9en H (2013) ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro. Pharmgenomics Pers Med 6:63\u201372","journal-title":"Pharmgenomics Pers Med"},{"issue":"5","key":"4891_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/mp200617z","volume":"9","author":"HGM Wittgen","year":"2012","unstructured":"Wittgen HGM, Greupink R, van den Heuvel JJMW, van den Broek PHH, Dinter-Heidorn H, Koenderink JB, Russel FGM (2012) Exploiting Transport Activity of P-Glycoprotein at the Blood\u2013Brain Barrier for the Development of Peripheral Cannabinoid Type 1 Receptor Antagonists. Mol Pharm 9(5):1351\u20131360","journal-title":"Mol Pharm"},{"issue":"4","key":"4891_CR19","doi-asserted-by":"publisher","first-page":"e18438","DOI":"10.1371\/journal.pone.0018438","volume":"6","author":"HA Mutsaers","year":"2011","unstructured":"Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, Wetzels JF et al (2011) Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS ONE 6(4):e18438","journal-title":"PLoS ONE"},{"issue":"4","key":"4891_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/mol.107.043661","volume":"74","author":"AA El-Sheikh","year":"2008","unstructured":"El-Sheikh AA, van den Heuvel JJ, Krieger E, Russel FG, Koenderink JB (2008) Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4\/ABCC4). Mol Pharmacol 74(4):964\u2013971","journal-title":"Mol Pharmacol"},{"key":"4891_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tube.2015.08.004","volume":"96","author":"LHM te Brake","year":"2016","unstructured":"te Brake LHM, Russel FGM, van den Heuvel JJMW, de Knegt GJ, de Steenwinkel JE, Burger DM et al (2016) Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Tuberculosis 96:150\u2013157","journal-title":"Tuberculosis"},{"key":"4891_CR22","doi-asserted-by":"publisher","first-page":"106128","DOI":"10.1016\/j.tiv.2025.106128","volume":"109","author":"L le Roux-Pullen","year":"2025","unstructured":"le Roux-Pullen L, van den Heuvel J, Dubbelboer IR, Russel FGM, Gehring R, Koenderink JB (2025) Inhibitory potential of phytochemicals on species-specific breast cancer resistance protein transport activity. Toxicol Vitro 109:106128","journal-title":"Toxicol Vitro"},{"issue":"5","key":"4891_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jvp.13460","volume":"47","author":"L Le Roux-Pullen","year":"2024","unstructured":"Le Roux-Pullen L, Van den Heuvel J, Jonis NB, Scheer-Weijers T, Dubbelboer IR, Koenderink JB et al (2024) In vitro screening model for compound interactions with human and dairy animal BCRP orthologs. J Vet Pharmacol Ther 47(5):437\u2013441","journal-title":"J Vet Pharmacol Ther"},{"issue":"9","key":"4891_CR24","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1007\/s00204-020-02793-4","volume":"94","author":"JB Koenderink","year":"2020","unstructured":"Koenderink JB, van den Heuvel J, Bilos A, Vredenburg G, Vermeulen NPE, Russel FGM (2020) Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates. Arch Toxicol 94(9):3027\u20133032","journal-title":"Arch Toxicol"},{"issue":"6","key":"4891_CR25","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1128\/AAC.02931-15","volume":"60","author":"VJ Lempers","year":"2016","unstructured":"Lempers VJ, van den Heuvel JJ, Russel FG, Aarnoutse RE, Burger DM, Br\u00fcggemann RJ, Koenderink JB (2016) Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother 60(6):3372\u20133379","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4891_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phrs.2003.11.007","volume":"50","author":"HC Cheng","year":"2004","unstructured":"Cheng HC (2004) The influence of cooperativity on the determination of dissociation constants: examination of the Cheng-Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations. Pharmacol Res 50(1):21\u201340","journal-title":"Pharmacol Res"},{"issue":"5","key":"4891_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jvp.13460","volume":"47","author":"L Le Roux-Pullen","year":"2024","unstructured":"Le Roux-Pullen L, Van den Heuvel JJMW, Jonis NB, Scheer-Weijers T, Dubbelboer IR, Koenderink JB et al (2024) In vitro screening model for compound interactions with human and dairy animal BCRP orthologs. J Vet Pharmacol Ther 47(5):437\u2013441","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"4891_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/toxsci\/kfs307","volume":"131","author":"E Gozalpour","year":"2013","unstructured":"Gozalpour E, Wittgen HG, van den Heuvel JJ, Greupink R, Russel FG, Koenderink JB (2013) Interaction of digitalis-like compounds with p-glycoprotein. Toxicol Sci 131(2):502\u2013511","journal-title":"Toxicol Sci"},{"key":"4891_CR29","unstructured":"FDA. Highlights of prescribing information scemblix (asciminib) (2024) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215358s000Orig2lbl.pdf"},{"key":"4891_CR30","unstructured":"FDA. NDA\/BLA Multi-disciplinary Review and Evaluation Scemblix Asciminib: FDA (2021) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215358Orig1s000,Orig2s000MultidisciplineR.pdf"},{"issue":"2","key":"4891_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1365-2125.2004.02117.x","volume":"58","author":"O Kretz","year":"2004","unstructured":"Kretz O, Weiss HM, Schumacher MM, Gross G (2004) In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 58(2):212\u2013216","journal-title":"Br J Clin Pharmacol"},{"key":"4891_CR32","doi-asserted-by":"crossref","unstructured":"Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al (2004) Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients. J Clin Oncol. 22(5):935\u2013942","DOI":"10.1200\/JCO.2004.03.050"},{"issue":"9","key":"4891_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/bdd.1821","volume":"33","author":"B Xia","year":"2012","unstructured":"Xia B, Heimbach T, He H, Lin TH (2012) Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos 33(9):536\u2013549","journal-title":"Biopharm Drug Dispos"},{"issue":"18","key":"4891_CR34","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-09-0542","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R et al (2009) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 15(18):5910\u20135916","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4891_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","volume":"61","author":"AV Kamath","year":"2008","unstructured":"Kamath AV, Wang J, Lee FY, Marathe PH (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 61(3):365\u2013376","journal-title":"Cancer Chemother Pharmacol"},{"key":"4891_CR36","first-page":"85","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 5:85\u201397","journal-title":"Clin Pharmacol"},{"issue":"10","key":"4891_CR37","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","volume":"55","author":"R Abbas","year":"2016","unstructured":"Abbas R, Hsyu P-H (2016) Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. Clin Pharmacokinet 55(10):1191\u20131204","journal-title":"Clin Pharmacokinet"},{"key":"4891_CR38","unstructured":"FDA. Clinical pharmacology and biopharmaceutics review(s) application number 203341Orig1s000 Bosutinib (Bosulif) FDA (2011) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203341orig1s000clinpharmr.pdf"},{"key":"4891_CR39","unstructured":"FDA Highlights of prescribing information ICLUSIG ponatinib 2024 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/203469s037lbl.pdf"},{"key":"4891_CR40","unstructured":"FDA. Clinical pharmacology and biopharmaceutics review(s) application number 203469Orig1s000 Iclusig, ponatinib: FDA (2012) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203469orig1s000clinpharmr.pdf"},{"issue":"3","key":"4891_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4149\/neo_2009_03_202","volume":"56","author":"K Czyzewski","year":"2009","unstructured":"Czyzewski K, Styczynski J (2009) Imatinib is a substrate for various multidrug resistance proteins. Neoplasma 56(3):202\u2013207","journal-title":"Neoplasma"},{"key":"4891_CR42","doi-asserted-by":"crossref","unstructured":"Maia RC, Vasconcelos FC, Souza PS, Rumjanek VM (2018) Towards Comprehension of the ABCB1\/P-Glycoprotein Role in Chronic Myeloid Leukemia. Molecules23(1):119","DOI":"10.3390\/molecules23010119"},{"issue":"7","key":"4891_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bdd.2022","volume":"37","author":"R D\u2019Cunha","year":"2016","unstructured":"D\u2019Cunha R, Bae S, Murry DJ, An G (2016) TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. Biopharm Drug Dispos 37(7):397\u2013408","journal-title":"Biopharm Drug Dispos"},{"issue":"17","key":"4891_CR44","doi-asserted-by":"publisher","first-page":"13423","DOI":"10.18632\/oncotarget.24393","volume":"9","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Saunders VA, Branford S, White DL, Hughes TP (2018) The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget 9(17):13423\u201313437","journal-title":"Oncotarget"},{"issue":"8","key":"4891_CR45","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/leu.2015.35","volume":"29","author":"L Lu","year":"2015","unstructured":"Lu L, Saunders VA, Leclercq TM, Hughes TP, White DL (2015) Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia 29(8):1792\u20131794","journal-title":"Leukemia"},{"issue":"9","key":"4891_CR46","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 104(9):2940\u20132942","journal-title":"Blood"},{"issue":"3","key":"4891_CR47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","volume":"95","author":"LN Eadie","year":"2014","unstructured":"Eadie LN, Hughes TP, White DL (2014) Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther 95(3):294\u2013306","journal-title":"Clin Pharmacol Ther"},{"key":"4891_CR48","unstructured":"EMA, Scemblix EPAR - product Information 2025 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/scemblix-epar-product-information_en.pdf"},{"issue":"2","key":"4891_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","volume":"78","author":"AK Tiwari","year":"2009","unstructured":"Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr., Chen X, Chen ZS (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters. Biochem Pharmacol 78(2):153\u2013161","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4891_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12918-017-0498-x","volume":"11","author":"J Bender","year":"2017","unstructured":"Bender J, Fang J, Simon R (2017) A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors. BMC Syst Biol 11(1):108","journal-title":"BMC Syst Biol"},{"issue":"6","key":"4891_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3324\/haematol.2012.070268","volume":"98","author":"KH Devendra","year":"2013","unstructured":"Devendra KH, Verity AS, Eva N, Douglas DR, Deborah LW, Timothy PH (2013) Dasatinib targets chronic myeloid leukemia-CD34\u2009+\u2009progenitors as effectively as it targets mature cells. Haematologica 98(6):896\u2013900","journal-title":"Haematologica"},{"issue":"9","key":"4891_CR52","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1535-7163.MCT-12-0302","volume":"11","author":"R Sen","year":"2012","unstructured":"Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L et al (2012) The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 11(9):2033\u20132044","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4891_CR53","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S et al (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21(6):1267\u20131275","journal-title":"Leukemia"},{"issue":"6","key":"4891_CR54","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, V\u00e1rady G, Ujhelly O, Schuetz JD, V\u00e1radi A et al (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65(6):1485\u20131495","journal-title":"Mol Pharmacol"},{"key":"4891_CR55","unstructured":"Pfizer (2012) Highlights of prescribing information BOSULIF (bosutinib) tablets and capsules, for oral use. Pfizer laboratories Div Pfizer inc. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=884"},{"key":"4891_CR56","unstructured":"EMA, Bosulif EPAR - product information 2025 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif"},{"key":"4891_CR57","doi-asserted-by":"publisher","first-page":"117114","DOI":"10.1016\/j.biopha.2024.117114","volume":"178","author":"M-J Kang","year":"2024","unstructured":"Kang M-J, Kim MJ, Seol Y, Chang J-E, Lee K-R, Chae Y-J (2024) Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib. Biomed Pharmacother 178:117114","journal-title":"Biomed Pharmacother"},{"key":"4891_CR58","unstructured":"EMA, Iclusig EPAR - Product Information 2025 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf"},{"issue":"7","key":"4891_CR59","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1124\/dmd.110.037812","volume":"39","author":"HGM Wittgen","year":"2011","unstructured":"Wittgen HGM, van den Heuvel JJMW, van den Broek PHH, Dinter-Heidorn H, Koenderink JB, Russel FGM (2011) Cannabinoid Type 1 Receptor Antagonists Modulate Transport Activity of Multidrug Resistance-Associated Proteins MRP1, MRP2, MRP3, and MRP4. Drug Metab Dispos 39(7):1298\u20131306","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4891_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","volume":"17","author":"Q Mao","year":"2015","unstructured":"Mao Q, Unadkat JD (2015) Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2013an update. Aaps j 17(1):65\u201382","journal-title":"Aaps j"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04891-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04891-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04891-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:07:48Z","timestamp":1778598468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04891-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4891"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04891-z","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}